Our latest articles
Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
Eisai is rewarded for doubling down on lecanemab with an apparent win that endorses 20 years of research.
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
But the group has a long way to go to set up a showdown with Eylea.
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
The developer has now struck two rich deals for the antibiotics space, a field that infrequently sees big sums change hands.
Neither project is an obvious candidate for phase 3, so more mid-stage trials are planned.